Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results